Testolactone

In the US, Testolactone (testolactone systemic) is a member of the following drug classes: aromatase inhibitors, hormones/antineoplastics and is used to treat Breast Cancer, Palliative.

US matches:

• Testolactone

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0000968-93-4

Chemical Formula

C19-H24-O3

Molecular Weight

300

Therapeutic Category

Androgen

Chemical Name

D-Homo-17a-oxaandrosta-1,4-diene-3,17-dione

Foreign Names

• Testolactonum (Latin)
• Testolacton (German)
• Testolactone (French)
• Testolactona (Spanish)

Generic Names

• Testolactone (OS: USAN)
• NSC 23759 (IS)
• SQ 9538 (IS)
• Testolactone (PH: USP 32)

Brand Name

• Teslac
  Bristol-Myers Squibb, United States

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Probenecid Synco

Probenecid Synco may be available in the countries listed below.

Ingredient matches for Probenecid Synco

Probenecid

Probenecid is reported as an ingredient of Probenecid Synco in the following countries:

• Hong Kong

International Drug Name Search

Gonadotraphon FSH

Gonadotraphon FSH may be available in the countries listed below.

Ingredient matches for Gonadotraphon FSH

Gonadotrophin, Serum

Gonadotrophin, Serum is reported as an ingredient of Gonadotraphon FSH in the following countries:

• Bahrain


• Cyprus


• Libya


• United Arab Emirates

International Drug Name Search

Cafcit

In the US, Cafcit (caffeine systemic) is a member of the drug class CNS stimulants and is used to treat Apnea of Prematurity and Hypersomnia.

US matches:

• Cafcit Solution


• Cafcit

Ingredient matches for Cafcit

Caffeine

Caffeine is reported as an ingredient of Cafcit in the following countries:

• Greece

Caffeine citrate (a derivative of Caffeine) is reported as an ingredient of Cafcit in the following countries:

• United States

International Drug Name Search

Iopidine

Iopidine is a brand name of apraclonidine ophthalmic, approved by the FDA in the following formulation(s):

IOPIDINE (apraclonidine hydrochloride - solution/drops; ophthalmic)

• 
  Manufacturer: ALCON
  
  Approval date: December 31, 1987
  
  Strength(s): EQ 1% BASE ^[RLD]


• 
  Manufacturer: ALCON
  
  Approval date: July 30, 1993
  
  Strength(s): EQ 0.5% BASE ^[RLD][AT]

Has a generic version of Iopidine been approved?

Yes. The following products are equivalent to Iopidine:

apraclonidine hydrochloride solution/drops; ophthalmic

• 
  Manufacturer: AKORN INC
  
  Approval date: March 12, 2009
  
  Strength(s): EQ 0.5% BASE ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Iopidine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Iopidine.

See also...

• Iopidine Drops Consumer Information (Wolters Kluwer)
• Iopidine Consumer Information (Cerner Multum)
• Iopidine Advanced Consumer Information (Micromedex)
• Iopidine AHFS DI Monographs (ASHP)
• Apraclonidine Drops Consumer Information (Wolters Kluwer)
• Apraclonidine ophthalmic Consumer Information (Cerner Multum)
• Apraclonidine Ophthalmic Advanced Consumer Information (Micromedex)
• Apraclonidine Hydrochloride AHFS DI Monographs (ASHP)

Flagyl

In some countries, this medicine may only be approved for veterinary use.

In the US, Flagyl (metronidazole systemic) is a member of the following drug classes: amebicides, miscellaneous antibiotics and is used to treat Amebiasis, Aspiration Pneumonia, Bacteremia, Bacterial Infection, Bone infection, Crohn's Disease - Acute, Crohn's Disease - Maintenance, Deep Neck Infection, Dental Abscess, Diverticulitis, Dracunculiasis, Endocarditis, Giardiasis, Helicobacter Pylori Infection, Intraabdominal Infection, Joint Infection, Meningitis, Pelvic Inflammatory Disease, Peritonitis, Pneumonia, Pseudomembranous Colitis, Skin Infection, Surgical Prophylaxis and Trichomoniasis.

US matches:

• Flagyl


• Flagyl Capsules


• Flagyl ER Extended-Release Tablets


• Flagyl 375


• Flagyl ER


• Flagyl I.V.


• Flagyl I.V. Intravenous


• Flagyl I.V. RTU


• Flagyl I.V. RTU Intravenous


• Flagyl Oral, Intravenous


• Flagyl Vaginal


• Flagyl 375 Capsules


• Flagyl Injection

UK matches:

• Flagyl Suppositories 500 mg and 1.0 g.
• Flagyl 1g Suppositories (SPC)
• Flagyl 400mg Tablets (SPC)
• Flagyl 500mg Suppositories (SPC)
• Flagyl 500mg/100ml Solution for Infusion (SPC)
• Flagyl S Suspension (SPC)
• Flagyl Tablets 200 mg (SPC)

Ingredient matches for Flagyl

Metronidazole

Metronidazole is reported as an ingredient of Flagyl in the following countries:

• Argentina


• Australia


• Bahrain


• Bangladesh


• Belgium


• Benin


• Brazil


• Bulgaria


• Burkina Faso


• Cameroon


• Canada


• Central African Republic


• Chad


• Chile


• Colombia


• Congo


• Costa Rica


• Cote D'ivoire


• Denmark


• Dominican Republic


• Ecuador


• El Salvador


• Finland


• France


• Gabon


• Georgia


• Germany


• Ghana


• Greece


• Guatemala


• Guinea


• Honduras


• Hong Kong


• Iceland


• India


• Indonesia


• Ireland


• Israel


• Italy


• Japan


• Kenya


• Luxembourg


• Madagascar


• Malaysia


• Mali


• Malta


• Mauritania


• Mauritius


• Mexico


• Netherlands


• New Zealand


• Niger


• Nigeria


• Norway


• Oman


• Panama


• Peru


• Portugal


• Romania


• Russian Federation


• Senegal


• Singapore


• South Africa


• Sweden


• Switzerland


• Taiwan


• Thailand


• Togo


• Tunisia


• Turkey


• Uganda


• United Kingdom


• United States


• Vietnam


• Zaire


• Zimbabwe

Metronidazole benzoate (a derivative of Metronidazole) is reported as an ingredient of Flagyl in the following countries:

• Denmark


• India


• Malta


• Netherlands


• New Zealand


• Romania


• Spain


• Sweden


• United Kingdom

Metronidazole hydrochloride (a derivative of Metronidazole) is reported as an ingredient of Flagyl in the following countries:

• United States

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Neblic

Neblic may be available in the countries listed below.

Ingredient matches for Neblic

Azithromycin

Azithromycin dihydrate (a derivative of Azithromycin) is reported as an ingredient of Neblic in the following countries:

• Argentina

International Drug Name Search

Framycétine

Framycétine may be available in the countries listed below.

Ingredient matches for Framycétine

Framycetin

Framycétine (DCF) is known as Framycetin in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Bingast

Bingast may be available in the countries listed below.

Ingredient matches for Bingast

Sucralfate

Sucralfate is reported as an ingredient of Bingast in the following countries:

• Japan

International Drug Name Search

Carbimazolo

Carbimazolo may be available in the countries listed below.

Ingredient matches for Carbimazolo

Carbimazole

Carbimazolo (DCIT) is also known as Carbimazole (Rec.INN)

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Ranexa

Ranexa is a brand name of ranolazine, approved by the FDA in the following formulation(s):

RANEXA (ranolazine - tablet, extended release; oral)

• 
  Manufacturer: GILEAD
  
  Approval date: January 27, 2006
  
  Strength(s): 500MG
  


• 
  Manufacturer: GILEAD
  
  Approval date: February 12, 2007
  
  Strength(s): 1GM ^[RLD]

Has a generic version of Ranexa been approved?

No. There is currently no therapeutically equivalent version of Ranexa available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ranexa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for administering a sustained release ranolanolazine formulation
  Patent 6,303,607
  Issued: October 16, 2001
  Inventor(s): Wolff; Andrew A. & Baker; Fiona & Langridge; John Richard
  Assignee(s): CV Therapeutics, Inc.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Patent use: TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
  
  



• 
  Sustained release ranolazine formulations
  Patent 6,369,062
  Issued: April 9, 2002
  Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
  Assignee(s): CV Therapeutics, Inc.
  Syntex (USA) Inc.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Drug product
    ✓ 
    Sponsor has requested patent be delisted
  
  
  
  • May 27, 2019
    
    ✓ 
    Drug product
  
  



• 
  Methods for treating angina with ranolazine
  Patent 6,479,496
  Issued: November 12, 2002
  Inventor(s): Andrew A.; Wolff
  Assignee(s): CV Therapeutics, Inc.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Patent use: TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
  
  



• 
  Sustained release ranolazine formulations
  Patent 6,503,911
  Issued: January 7, 2003
  Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
  Assignee(s): CV Therapeutics, Inc.
  Syntex USA, Inc.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Drug product
  
  



• 
  Sustained release ranolazine formulations
  Patent 6,525,057
  Issued: February 25, 2003
  Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
  Assignee(s): CV Therapeutics, Inc.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Patent use: TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
  
  



• 
  Sustained release ranolazine formulations
  Patent 6,562,826
  Issued: May 13, 2003
  Inventor(s): Andrew A.; Wolff
  Assignee(s): CV Therapeutics, Inc.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Patent use: TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
  
  



• 
  Sustained release ranolazine formulations
  Patent 6,617,328
  Issued: September 9, 2003
  Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
  Assignee(s): CV Therapeutics, Inc
  Syntex (USA), LLC
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Drug product
  
  



• 
  Sustained release ranolazine formulations
  Patent 6,620,814
  Issued: September 16, 2003
  Inventor(s): Andrew A.; Wolff & Fiona; Baker & John; Langridge
  Assignee(s): CV Therapeutics, Inc.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Patent use: TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
  
  



• 
  Sustained release ranolazine formulations
  Patent 6,852,724
  Issued: February 8, 2005
  Inventor(s): Wolff; Andrew A.
  Assignee(s): CV Therapeutics, Inc.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Patent use: TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
  
  



• 
  Sustained release ranolazine formulations
  Patent 6,864,258
  Issued: March 8, 2005
  Inventor(s): Wolff; Andrew A.
  A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
  
  Patent expiration dates:
  
  
  • May 27, 2019
    
    ✓ 
    Patent use: TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 27, 2011 - NEW CHEMICAL ENTITY
  
  

See also...

• Ranexa Consumer Information (Drugs.com)
• Ranexa Consumer Information (Wolters Kluwer)
• Ranexa Consumer Information (Cerner Multum)
• Ranexa Advanced Consumer Information (Micromedex)
• Ranexa AHFS DI Monographs (ASHP)
• Ranolazine Consumer Information (Wolters Kluwer)
• Ranolazine Consumer Information (Cerner Multum)
• Ranolazine Advanced Consumer Information (Micromedex)
• Ranolazine AHFS DI Monographs (ASHP)

Ciclofosfamida

Ciclofosfamida may be available in the countries listed below.

Ingredient matches for Ciclofosfamida

Cyclophosphamide

Cyclophosphamide is reported as an ingredient of Ciclofosfamida in the following countries:

• Chile


• Peru

International Drug Name Search

Cromolerg

Cromolerg may be available in the countries listed below.

Ingredient matches for Cromolerg

Cromoglicic Acid

Cromoglicic Acid disodium salt (a derivative of Cromoglicic Acid) is reported as an ingredient of Cromolerg in the following countries:

• Brazil

International Drug Name Search

Paromomicina

Paromomicina may be available in the countries listed below.

Ingredient matches for Paromomicina

Paromomycin

Paromomicina (DCIT) is known as Paromomycin in the US.

International Drug Name Search

Glossary

DCIT	Denominazione Comune Italiana

Click for further information on drug naming conventions and International Nonproprietary Names.

Argosulfan

Argosulfan may be available in the countries listed below.

Ingredient matches for Argosulfan

Sulfathiazole

Sulfathiazole is reported as an ingredient of Argosulfan in the following countries:

• Bulgaria


• Georgia


• Hungary


• Latvia


• Lithuania


• Russian Federation

Sulfathiazole sodium (a derivative of Sulfathiazole) is reported as an ingredient of Argosulfan in the following countries:

• Poland

International Drug Name Search

Biolent

Biolent may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Biolent

Carbachol

Carbachol is reported as an ingredient of Biolent in the following countries:

• Poland

International Drug Name Search

Glimepirid-1A Pharma

Glimepirid-1A Pharma may be available in the countries listed below.

Ingredient matches for Glimepirid-1A Pharma

Glimepiride

Glimepiride is reported as an ingredient of Glimepirid-1A Pharma in the following countries:

• Austria


• Germany


• Hungary

International Drug Name Search

Rabeloc

Rabeloc may be available in the countries listed below.

Ingredient matches for Rabeloc

Rabeprazole

Rabeprazole sodium salt (a derivative of Rabeprazole) is reported as an ingredient of Rabeloc in the following countries:

• India


• Sri Lanka

International Drug Name Search

Triamcinolone (acétonide de)

Triamcinolone (acétonide de) may be available in the countries listed below.

Ingredient matches for Triamcinolone (acétonide de)

Triamcinolone

Triamcinolone (acétonide de) (DCF) is known as Triamcinolone in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Stator

Stator may be available in the countries listed below.

Ingredient matches for Stator

Atorvastatin

Atorvastatin calcium (a derivative of Atorvastatin) is reported as an ingredient of Stator in the following countries:

• Indonesia

International Drug Name Search

Vijomicin

Vijomicin may be available in the countries listed below.

Ingredient matches for Vijomicin

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Vijomicin in the following countries:

• El Salvador


• Guatemala


• Honduras


• Nicaragua


• Panama

International Drug Name Search

Miansérine EG

Miansérine EG may be available in the countries listed below.

Ingredient matches for Miansérine EG

Mianserin

Mianserin hydrochloride (a derivative of Mianserin) is reported as an ingredient of Miansérine EG in the following countries:

• France

International Drug Name Search

Cefixim Domesco

Cefixim Domesco may be available in the countries listed below.

Ingredient matches for Cefixim Domesco

Cefixime

Cefixime is reported as an ingredient of Cefixim Domesco in the following countries:

• Vietnam

International Drug Name Search

Uniphyl LA

Uniphyl LA may be available in the countries listed below.

Ingredient matches for Uniphyl LA

Theophylline

Theophylline is reported as an ingredient of Uniphyl LA in the following countries:

• Japan

International Drug Name Search

Tuberbut

Tuberbut may be available in the countries listed below.

Ingredient matches for Tuberbut

Tobramycin

Tobramycin is reported as an ingredient of Tuberbut in the following countries:

• Argentina

International Drug Name Search

Eparina Calcica Mylan

Eparina Calcica Mylan may be available in the countries listed below.

Ingredient matches for Eparina Calcica Mylan

Heparin

Heparin calcium salt (a derivative of Heparin) is reported as an ingredient of Eparina Calcica Mylan in the following countries:

• Italy

International Drug Name Search

Nac SR

Nac SR may be available in the countries listed below.

Ingredient matches for Nac SR

Diclofenac

Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Nac SR in the following countries:

• India

International Drug Name Search

Boncordin

Boncordin may be available in the countries listed below.

Ingredient matches for Boncordin

Benazepril

Benazepril hydrochloride (a derivative of Benazepril) is reported as an ingredient of Boncordin in the following countries:

• Argentina

International Drug Name Search

Pretanix

Pretanix may be available in the countries listed below.

Ingredient matches for Pretanix

Indapamide

Indapamide is reported as an ingredient of Pretanix in the following countries:

• Hungary

International Drug Name Search

Chlormézanone

Chlormézanone may be available in the countries listed below.

Ingredient matches for Chlormézanone

Chlormezanone

Chlormézanone (DCF) is known as Chlormezanone in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Gabapentin Germed

Gabapentin Germed may be available in the countries listed below.

Ingredient matches for Gabapentin Germed

Gabapentin

Gabapentin is reported as an ingredient of Gabapentin Germed in the following countries:

• Italy

International Drug Name Search

Diphos

Diphos may be available in the countries listed below.

Ingredient matches for Diphos

Etidronic Acid

Etidronic Acid disodium salt (a derivative of Etidronic Acid) is reported as an ingredient of Diphos in the following countries:

• Germany

International Drug Name Search

Alglucosidase Alfa

In the US, Alglucosidase Alfa (alglucosidase alfa systemic) is a member of the drug class lysosomal enzymes and is used to treat Pompe disease.

US matches:

• Alglucosidase Alfa


• Alglucosidase alfa injection


• Alglucosidase alfa Intravenous

Ingredient matches for Alglucosidase Alfa

Alglucosidase Alfa

Alglucosidase Alfa (USAN) is known as Alglucosidase Alfa in the US.

International Drug Name Search

Glossary

USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Losartas

Losartas may be available in the countries listed below.

Ingredient matches for Losartas

Losartan

Losartan is reported as an ingredient of Losartas in the following countries:

• Peru

Losartan potassium salt (a derivative of Losartan) is reported as an ingredient of Losartas in the following countries:

• Myanmar

International Drug Name Search

Loridem

Loridem may be available in the countries listed below.

Ingredient matches for Loridem

Lorazepam

Lorazepam is reported as an ingredient of Loridem in the following countries:

• Belgium


• Luxembourg

International Drug Name Search

Sulperason

Sulperason may be available in the countries listed below.

Ingredient matches for Sulperason

Cefoperazone

Cefoperazone is reported as an ingredient of Sulperason in the following countries:

• Russian Federation

Sulbactam

Sulbactam is reported as an ingredient of Sulperason in the following countries:

• Russian Federation

International Drug Name Search

Gaosédal Codéine

Gaosédal Codéine may be available in the countries listed below.

Ingredient matches for Gaosédal Codéine

Codeine

Codeine phosphate hemihydrate (a derivative of Codeine) is reported as an ingredient of Gaosédal Codéine in the following countries:

• France

Paracetamol

Paracetamol is reported as an ingredient of Gaosédal Codéine in the following countries:

• France

International Drug Name Search

Eraxis

Eraxis is a brand name of anidulafungin, approved by the FDA in the following formulation(s):

ERAXIS (anidulafungin - injectable; iv (infusion))

• 
  Manufacturer: VICURON
  
  Approval date: February 17, 2006
  
  Strength(s): 50MG/VIAL ^[RLD]


• 
  Manufacturer: VICURON
  
  Approval date: November 14, 2006
  
  Strength(s): 100MG/VIAL ^[RLD]

Has a generic version of Eraxis been approved?

No. There is currently no therapeutically equivalent version of Eraxis available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eraxis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Cyclic peptide antifungal agents
  Patent 5,965,525
  Issued: October 12, 1999
  Inventor(s): Burkhardt; Frederick J. & Debono; Manuel & Nissen; Jeffrey S. & Turner, Jr.; William W.
  Assignee(s): Eli Lilly and Company
  Provided are compounds of the formula (1): ##STR1## wherein R' is hydrogen, methyl or NH.sub.2 C(O)CH.sub.2 --; R" and R'" are independently methyl or hydrogen; R and R.sup.y are independently hydroxy or hydrogen; R.sub.1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R.sub.7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R.sub.2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
  
  Patent expiration dates:
  
  
  • February 17, 2020
    
    ✓ 
    Patent use: TREATMENT OF FUNGAL INFECTIONS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Cyclic peptide antifungal agents and process for preparation thereof
  Patent 6,384,013
  Issued: May 7, 2002
  Inventor(s): Frederick J.; Burkhardt & Manuel; Debono & Jeffrey S.; Nissen & William W.; Turner, Jr.
  Assignee(s): Eli Lilly and Company
  Provided are compounds of the formula (1): wherein R′ is hydrogen, methyl or NH2C(O)CH2—; R″ and R′″ are independently methyl or hydrogen; R and Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a acyl side chain. Also provided are formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R═H) forms of the compounds.
  
  Patent expiration dates:
  
  
  • March 19, 2012
    
    ✓ 
    Drug substance
  
  



• 
  Cyclic peptide antifungal agents and process for preparation thereof
  Patent 6,743,777
  Issued: June 1, 2004
  Inventor(s): Frederick J.; Burkhardt & Manuel; Debono & Jeffrey S.; Nissen & William W.; Turner, Jr.
  Assignee(s): Eli Lilly and Company
  Provided are compounds of the formula (1): wherein R′ is hydrogen, methyl or NH2C(O)CH2—; R″ and R′″ are independently methyl or hydrogen; R adn Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.
  
  Patent expiration dates:
  
  
  • March 19, 2012
    
    ✓ 
    Patent use: TREATMENT OF FUNGAL INFECTIONS
    ✓ 
    Drug product
  
  



• 
  Echinocandin pharmaceutical formulations containing micelle-forming surfactants
  Patent 6,960,564
  Issued: November 1, 2005
  Inventor(s): Milton; Nathaniel & Moder; Kenneth Philip & Sabatowski; James Lawrence & Sweetana; Stephanie Ann
  Assignee(s): Eli Lilly and Company
  Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
  
  Patent expiration dates:
  
  
  • April 12, 2021
    
    ✓ 
    Patent use: TREATMENT OF FUNGAL INFECTIONS
    ✓ 
    Drug product
  
  



• 
  Echinocandin pharmaceutical formulations containing micelle-forming surfactants
  Patent 7,709,444
  Issued: May 4, 2010
  Inventor(s): Milton; Nathaniel & Moder; Kenneth Philip & Sabatowski; James Lawrence & Sweetana; Stephanie Ann
  Assignee(s): Pfizer Inc.
  Pharmaceutical formulations are described comprising an echinocandin compound or echinocandin/carbohydrate complex and a pharmaceutically acceptable micelle-forming surfactant in a non-toxic aqueous solvent such that the solubilization of the echinocandin compound is optimized and the ability to freeze-dry the solution is maintained. Both the solution and freeze-dried formulations have increased stability. A bulking agent, tonicity agent buffer and/or a stabilizing agent may optionally be added to the formulations to further enhance the stability of the formulation.
  
  Patent expiration dates:
  
  
  • April 12, 2021
    
    ✓ 
    Patent use: TREATMENT OF FUNGAL INFECTIONS
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 17, 2011 - NEW CHEMICAL ENTITY
  
  

See also...

• Eraxis Consumer Information (Drugs.com)
• Eraxis Consumer Information (Wolters Kluwer)
• Eraxis Consumer Information (Cerner Multum)
• Eraxis Advanced Consumer Information (Micromedex)
• Eraxis AHFS DI Monographs (ASHP)
• Anidulafungin Consumer Information (Wolters Kluwer)
• Anidulafungin Consumer Information (Cerner Multum)
• Anidulafungin Intravenous Advanced Consumer Information (Micromedex)
• Anidulafungin AHFS DI Monographs (ASHP)

Colchicina Lirca

Colchicina Lirca may be available in the countries listed below.

Ingredient matches for Colchicina Lirca

Colchicine

Colchicine is reported as an ingredient of Colchicina Lirca in the following countries:

• Italy

International Drug Name Search

Lonazep

Lonazep may be available in the countries listed below.

Ingredient matches for Lonazep

Clonazepam

Clonazepam is reported as an ingredient of Lonazep in the following countries:

• Bangladesh


• India

International Drug Name Search

Pramiel

Pramiel may be available in the countries listed below.

Ingredient matches for Pramiel

Metoclopramide

Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Pramiel in the following countries:

• Japan

International Drug Name Search

Trimébutine Alter

Trimébutine Alter may be available in the countries listed below.

Ingredient matches for Trimébutine Alter

Trimebutine

Trimebutine maleate (a derivative of Trimebutine) is reported as an ingredient of Trimébutine Alter in the following countries:

• France

International Drug Name Search

Concor Cor

Concor Cor may be available in the countries listed below.

Ingredient matches for Concor Cor

Bisoprolol

Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Concor Cor in the following countries:

• Austria


• Bulgaria


• Croatia (Hrvatska)


• Czech Republic


• Georgia


• Hungary


• Lithuania


• Luxembourg


• Romania


• Russian Federation


• Vietnam

International Drug Name Search

Amoxicilline

Amoxicilline may be available in the countries listed below.

Ingredient matches for Amoxicilline

Amoxicillin

Amoxicilline (DCF) is known as Amoxicillin in the US.

International Drug Name Search

Glossary

DCF	Dénomination Commune Française

Click for further information on drug naming conventions and International Nonproprietary Names.

Aflamin

Aflamin may be available in the countries listed below.

Ingredient matches for Aflamin

Aceclofenac

Aceclofenac is reported as an ingredient of Aflamin in the following countries:

• Hungary

International Drug Name Search

Gliride

Gliride may be available in the countries listed below.

Ingredient matches for Gliride

Glimepiride

Glimepiride is reported as an ingredient of Gliride in the following countries:

• Colombia

International Drug Name Search

Glimépiride Zydus

Glimépiride Zydus may be available in the countries listed below.

Ingredient matches for Glimépiride Zydus

Glimepiride

Glimepiride is reported as an ingredient of Glimépiride Zydus in the following countries:

• France

International Drug Name Search

Ukaject

Ukaject may be available in the countries listed below.

Ingredient matches for Ukaject

Amikacin

Amikacin sulfate (a derivative of Amikacin) is reported as an ingredient of Ukaject in the following countries:

• Vietnam

International Drug Name Search

Cetazine

Cetazine may be available in the countries listed below.

Ingredient matches for Cetazine

Ceftazidime

Ceftazidime is reported as an ingredient of Cetazine in the following countries:

• Taiwan

International Drug Name Search

Gaster

Gaster may be available in the countries listed below.

Ingredient matches for Gaster

Famotidine

Famotidine is reported as an ingredient of Gaster in the following countries:

• China


• Indonesia


• Japan


• Taiwan

Omeprazole

Omeprazole is reported as an ingredient of Gaster in the following countries:

• Thailand

International Drug Name Search

Curoxim

Curoxim may be available in the countries listed below.

Ingredient matches for Curoxim

Cefuroxime

Cefuroxime sodium salt (a derivative of Cefuroxime) is reported as an ingredient of Curoxim in the following countries:

• Italy

International Drug Name Search

Glimepirid Sandoz

Glimepirid Sandoz may be available in the countries listed below.

Ingredient matches for Glimepirid Sandoz

Glimepiride

Glimepiride is reported as an ingredient of Glimepirid Sandoz in the following countries:

• Austria


• Czech Republic


• Finland


• Germany


• Lithuania


• Slovakia


• Sweden


• Switzerland

International Drug Name Search

Deltamethrin

In some countries, this medicine may only be approved for veterinary use.

Scheme

BAN

CAS registry number (Chemical Abstracts Service)

0052918-63-5

Chemical Formula

C22-H19-Br2-N-O3

Molecular Weight

505

Therapeutic Categories

Insecticide

Pediculocide

Chemical Name

(S)-α-Cyano-3-phenoxybenzyl-(1R,3R)-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropanecarboxylate

Foreign Name

• Deltamethrin (German)

Generic Names

• Deltamethrin (OS: BAN)
• Decamethrin (IS)
• Esbecythrin (IS)
• FMC 45498 (IS)
• NRDC 161 (IS)
• OMS 1998 (IS)
• RU 22974 (IS)
• Deltamethrin (PH: BP vet. 2007)

Brand Names

• Arrest (veterinary use)
  Virbac, Australia



• Blaze (veterinary use)
  Intervet / Schering-Plough Animal Health, New Zealand



• Bombard (veterinary use)
  Fort Dodge Australia, Australia



• Butox (veterinary use)
  Intervet, Belgium; Intervet, Germany; Intervet, France; Intervet, United Kingdom; Intervet, Ireland; Intervet, Italy; Intervet, Poland; Intervet Schering-Plough Animal Health, Portugal



• Clout (veterinary use)
  Afrivet, South Africa; Coopers Animal Health, Australia



• Coopafly (veterinary use)
  Coopers Animal Health, Australia



• Coopers Spot On (veterinary use)
  Essex Tierarznei, Poland



• Coopers Tick Grease (Deltamethrin and Piperonyl Butoxide (veterinary use))
  Afrivet, South Africa



• Coopers (veterinary use)
  Coopers Animal Health, Australia



• Coopersect (veterinary use)
  Schering-Plough Animal, Norway; Vetcare, Finland



• Decaspot (Deltamethrin and Piperonyl Butoxide (veterinary use))
  Afrivet, South Africa



• Decatix (veterinary use)
  Afrivet, South Africa



• Delete (Deltamethrin and Amitraz, + Piperonyl Butoxide (veterinary use))
  Intervet, South Africa



• Delete (Deltamethrin and Piperonyl Butoxide (veterinary use))
  Intervet, South Africa



• Delete (veterinary use)
  Intervet, South Africa



• Deltab (veterinary use)
  Intervet, South Africa



• Deltacid
  Solvay, Brazil



• Equifly (veterinary use)
  Bomac Animal Health, Australia



• K-Othrine Flow (veterinary use)
  Bayer CropSciene, Italy



• Latroxin (veterinary use)
  Serumber, Germany



• Rambosal (veterinary use)
  Interhyg, Germany



• Scalibor (veterinary use)
  Intervet, Austria; Intervet, Belgium; Intervet, Germany; Intervet, Finland; Intervet, France; Intervet, United Kingdom; Intervet, Italy; Intervet, Netherlands; Intervet, Norway; Intervet, Sweden; Intervet International B.V., Luxembourg; Intervet Schering-Plough Animal Health, Portugal; Veterinaria, Switzerland



• Spot on Insecticide (veterinary use)
  Schering-Plough, Ireland; Schering-Plough Veterinary, United Kingdom



• Sputop (veterinary use)
  Schering-Plough Animal Health, Belgium



• Stampede (veterinary use)
  Intervet / Schering-Plough Animal Health, New Zealand



• Tixafly (veterinary use)
  Coopers Animal Health, Australia



• Triatix (Deltamethrin and Amitraz, + Piperonyl Butoxide (veterinary use))
  Afrivet, South Africa



• Versatrine (veterinary use)
  Pfizer Santé Animale, France



• Wipe Out (veterinary use)
  Afrivet, South Africa



• Wipeout (veterinary use)
  Intervet / Schering-Plough Animal Health, New Zealand

International Drug Name Search

Glossary

BAN	British Approved Name
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Lonine

Lonine may be available in the countries listed below.

Ingredient matches for Lonine

Etodolac

Etodolac is reported as an ingredient of Lonine in the following countries:

• Greece

International Drug Name Search

Glimepirid-Isis

Glimepirid-Isis may be available in the countries listed below.

Ingredient matches for Glimepirid-Isis

Glimepiride

Glimepiride is reported as an ingredient of Glimepirid-Isis in the following countries:

• Germany

International Drug Name Search

Tensanil

Tensanil may be available in the countries listed below.

Ingredient matches for Tensanil

Benazepril

Benazepril hydrochloride (a derivative of Benazepril) is reported as an ingredient of Tensanil in the following countries:

• Italy

International Drug Name Search

Glibenclamida Best

Glibenclamida Best may be available in the countries listed below.

Ingredient matches for Glibenclamida Best

Glibenclamide

Glibenclamide is reported as an ingredient of Glibenclamida Best in the following countries:

• Colombia

International Drug Name Search

Cellumed

Cellumed may be available in the countries listed below.

Ingredient matches for Cellumed

Carmellose

Carmellose sodium salt (a derivative of Carmellose) is reported as an ingredient of Cellumed in the following countries:

• Germany

International Drug Name Search

Synalar 0.025% med Chinoform

Synalar 0.025% med Chinoform may be available in the countries listed below.

Ingredient matches for Synalar 0.025% med Chinoform

Clioquinol

Clioquinol is reported as an ingredient of Synalar 0.025% med Chinoform in the following countries:

• Denmark

Fluocinolone

Fluocinolone Acetonide is reported as an ingredient of Synalar 0.025% med Chinoform in the following countries:

• Denmark

International Drug Name Search

Vincristine-Richter

Vincristine-Richter may be available in the countries listed below.

Ingredient matches for Vincristine-Richter

Vinblastine

Vinblastine sulfate (a derivative of Vinblastine) is reported as an ingredient of Vincristine-Richter in the following countries:

• Russian Federation

Vincristine

Vincristine is reported as an ingredient of Vincristine-Richter in the following countries:

• Tunisia

International Drug Name Search

Finicort

Finicort may be available in the countries listed below.

Ingredient matches for Finicort

Fluprednidene

Fluprednidene 21-acetate (a derivative of Fluprednidene) is reported as an ingredient of Finicort in the following countries:

• Greece

Miconazole

Miconazole nitrate (a derivative of Miconazole) is reported as an ingredient of Finicort in the following countries:

• Greece

International Drug Name Search

Celmoleukin

Scheme

Rec.INN

CAS registry number (Chemical Abstracts Service)

0094218-72-1

Chemical Formula

C693-H1118-N178-O203-S7

Molecular Weight

15416

Therapeutic Categories

Antineoplastic agent

Immunomodulator

Chemical Name

Interleukin 2 (human clone pTIL2-21a, protein moiety)

Foreign Names

• Celmoleukinum (Latin)
• Celmoleukin (German)
• Celmoleukine (French)
• Celmoleukina (Spanish)

Generic Name

• Interleukin 2 (IS: IUPAC, WHO)

Brand Name

• Celeuk
  Takeda, Japan

International Drug Name Search

Glossary

IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Glimepirid Genericon

Glimepirid Genericon may be available in the countries listed below.

Ingredient matches for Glimepirid Genericon

Glimepiride

Glimepiride is reported as an ingredient of Glimepirid Genericon in the following countries:

• Austria

International Drug Name Search

Gentamicina Richet

Gentamicina Richet may be available in the countries listed below.

Ingredient matches for Gentamicina Richet

Gentamicin

Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Gentamicina Richet in the following countries:

• Argentina

International Drug Name Search

Citicolin H

Citicolin H may be available in the countries listed below.

Ingredient matches for Citicolin H

Citicoline

Citicoline is reported as an ingredient of Citicolin H in the following countries:

• Japan

International Drug Name Search

Parlodel

Parlodel is a brand name of bromocriptine, approved by the FDA in the following formulation(s):

PARLODEL (bromocriptine mesylate - capsule; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: March 1, 1982
  
  Strength(s): EQ 5MG BASE ^[RLD][AB]

PARLODEL (bromocriptine mesylate - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approved Prior to Jan 1, 1982
  
  Strength(s): EQ 2.5MG BASE ^[RLD][AB]

Has a generic version of Parlodel been approved?

Yes. The following products are equivalent to Parlodel:

bromocriptine mesylate capsule; oral

• 
  Manufacturer: MYLAN
  
  Approval date: April 4, 2005
  
  Strength(s): EQ 5MG BASE ^[AB]


• 
  Manufacturer: ZYDUS PHARMS USA INC
  
  Approval date: July 30, 2008
  
  Strength(s): EQ 5MG BASE ^[AB]

bromocriptine mesylate tablet; oral

• 
  Manufacturer: LEK PHARMS
  
  Approval date: January 13, 1998
  
  Strength(s): EQ 2.5MG BASE ^[AB]


• 
  Manufacturer: MYLAN
  
  Approval date: September 24, 2004
  
  Strength(s): EQ 2.5MG BASE ^[AB]


• 
  Manufacturer: PADDOCK LLC
  
  Approval date: October 1, 2008
  
  Strength(s): EQ 2.5MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Parlodel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Parlodel.

See also...

• Parlodel Consumer Information (Wolters Kluwer)
• Parlodel Consumer Information (Cerner Multum)
• Parlodel Advanced Consumer Information (Micromedex)
• Parlodel AHFS DI Monographs (ASHP)
• Bromocriptine Consumer Information (Wolters Kluwer)
• Bromocriptine Mesylate Consumer Information (Wolters Kluwer)
• Bromocriptine Consumer Information (Cerner Multum)
• Bromocriptine Advanced Consumer Information (Micromedex)
• Bromocriptine Mesylate AHFS DI Monographs (ASHP)

Flutamida Bexal

Flutamida Bexal may be available in the countries listed below.

Ingredient matches for Flutamida Bexal

Flutamide

Flutamide is reported as an ingredient of Flutamida Bexal in the following countries:

• Spain

International Drug Name Search

Gabapentin Almus

Gabapentin Almus may be available in the countries listed below.

Ingredient matches for Gabapentin Almus

Gabapentin

Gabapentin is reported as an ingredient of Gabapentin Almus in the following countries:

• Germany

International Drug Name Search

Sindipine

Sindipine may be available in the countries listed below.

Ingredient matches for Sindipine

Nifedipine

Nifedipine is reported as an ingredient of Sindipine in the following countries:

• Taiwan

International Drug Name Search

Dinalgen

Dinalgen may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Dinalgen

Ketoprofen

Ketoprofen is reported as an ingredient of Dinalgen in the following countries:

• Italy


• Poland

International Drug Name Search

Tempra

In the US, Tempra (acetaminophen systemic) is a member of the drug class miscellaneous analgesics and is used to treat Fever, Muscle Pain, Pain and Sciatica.

US matches:

• Tempra 1 Drops


• Tempra Quicklets oral/rectal


• Tempra oral/rectal

Ingredient matches for Tempra

Paracetamol

Paracetamol is reported as an ingredient of Tempra in the following countries:

• Canada


• Ethiopia


• Indonesia


• Luxembourg


• Mexico


• Philippines


• Venezuela

International Drug Name Search

Glimépiride BGR

Glimépiride BGR may be available in the countries listed below.

Ingredient matches for Glimépiride BGR

Glimepiride

Glimepiride is reported as an ingredient of Glimépiride BGR in the following countries:

• France

International Drug Name Search

Betaseron

In the US, Betaseron (interferon beta-1b systemic) is a member of the drug class interferons and is used to treat Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Colorectal Cancer and Multiple Sclerosis.

US matches:

• Betaseron


• Betaseron Solution

Ingredient matches for Betaseron

Interferon beta

Interferon beta Interferon beta-1b (a derivative of Interferon beta) is reported as an ingredient of Betaseron in the following countries:

• Canada


• Israel


• United States

International Drug Name Search

Folicil

Folicil may be available in the countries listed below.

Ingredient matches for Folicil

Folic Acid

Folic Acid is reported as an ingredient of Folicil in the following countries:

• Malta


• Portugal

International Drug Name Search

Glimepirid Actavis

Glimepirid Actavis may be available in the countries listed below.

Ingredient matches for Glimepirid Actavis

Glimepiride

Glimepiride is reported as an ingredient of Glimepirid Actavis in the following countries:

• Austria


• Czech Republic


• Denmark


• Estonia


• Finland


• Latvia


• Lithuania


• Slovakia


• Sweden


• Switzerland

International Drug Name Search

Guajazyl

Guajazyl may be available in the countries listed below.

Ingredient matches for Guajazyl

Guaifenesin

Guaifenesin is reported as an ingredient of Guajazyl in the following countries:

• Poland

International Drug Name Search

Gestodene

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

G03AA10,G03AB06

CAS registry number (Chemical Abstracts Service)

0060282-87-3

Chemical Formula

C21-H26-O2

Molecular Weight

310

Therapeutic Categories

Progestin

Contraceptive

Chemical Names

(17α)-13-Ethyl-17-hydroxy-18,19-dinor-17α-pregna-4,15-dien-20-yn-3-one

13-Ethyl-17beta-hydroxy-18,19-dinorpregn-4,15-dien-20-in-3-on (IUPAC)

13-Ethyl-17-hydroxy-18,19-dinor-17α-pregna-4,15-dien-20-yn-3-one (WHO)

17-Hydroxy-18-methyl-19-nor-17α-pregna-4,15-dien-20-yn-3-one

17α-ethynyl-13-ethyl-17beta-hydroxy-4,15-gonadiene-3-one

17α-ethynyl-17beta-hydroxy-18-methyl-4,15-estradien-3-one

17α-Ethynyl-217-hydroxy-18-methylestra-4,15-dien-3-one

18,19-Dinorpregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-

Pregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-18,19-dinor-, (17α)- (USAN)

Foreign Names

• Gestodenum (Latin)
• Gestoden (German)
• Gestodène (French)
• Gestodeno (Spanish)

Generic Names

• Gestodene (OS: BAN, USAN)
• Gestodène (OS: DCF)
• BRN 4237181 (IS)
• CCRIS 91889 (IS)
• EINECS 262-145-8 (IS)
• HSDB 3594 (IS)
• SH B 331 (IS: Schering)
• SHG 415 G (IS)
• Gestodene (PH: BP 2010)

Brand Names

• Arianna (Gestodene and Ethinylestradiol)
  Bayer, Italy



• Avaden (Gestodene and Estradiol hemihydrate)
  Bayer, Peru; Schering, Colombia; Schering, Dominican Republic



• Avadène (Gestodene and Estradiol)
  Bayer Santé, France



• Careza (Gestodene and Ethinylestradiol)
  ABL, Peru



• Carlin (Gestodene and Ethinylestradiol)
  Effik, France



• Ciclomex (Gestodene and Ethinylestradiol)
  Gynocare Limited, Vietnam; Gynopharm, Peru; Recalcine, Ecuador



• Efézial (Gestodene and Ethinylestradiol)
  Mylan, France



• Elleogest (Gestodene and Ethinylestradiol)
  Stragen Pharma, Switzerland



• Estinette (Gestodene and Ethinylestradiol)
  Effik, Switzerland; Effik, Italy



• Ethinylestradiol / Gestodeen A (Gestodene and Ethinylestradiol)
  Apothecon, Netherlands



• Ethinylestradiol / Gestodeen Berlipharm (Gestodene and Ethinylestradiol)
  Berlipharm, Netherlands



• Ethinylestradiol / Gestodeen Mylan (Gestodene and Ethinylestradiol)
  Mylan, Netherlands



• Ethinylestradiol / Gestodeen PCH (Gestodene and Ethinylestradiol)
  Pharmachemie, Netherlands



• Fedra (Gestodene and Ethinylestradiol)
  Bayer, Italy



• Felixita (Gestodene and Ethinylestradiol)
  Théramex, Monaco



• Femadiol-Mepha (Gestodene and Ethinylestradiol)
  Mepha Pharma, Switzerland



• Femiane (Gestodene and Ethinylestradiol)
  Bayer, Peru; Schering, Colombia; Schering, Dominican Republic



• Femodeen (Gestodene and Ethinylestradiol)
  Bayer, Netherlands; Dr. Fisher, Netherlands; Eureco, Netherlands



• Femoden (Gestodene and Ethinylestradiol)
  Bayer, Bulgaria; Bayer, Latvia; Bayer Schering, Australia; Bayer Schering, Finland; Schering, Estonia; Schering, Hungary; Schering, Lithuania; Schering, Slovenia



• Femodene (Gestodene and Ethinylestradiol)
  Bayer, Belgium; Bayer, United Kingdom; Bayer, New Zealand; Bayer Animal Health, Luxembourg; Bayer Schering, South Africa



• Femodette (Gestodene and Ethinylestradiol)
  Bayer, United Kingdom



• Femovan (Gestodene and Ethinylestradiol)
  Bayer, Germany



• Gestinyl (Gestodene and Ethinylestradiol)
  Effik, Spain; Stragen, Denmark; Stragen Pharma, Switzerland



• Gestodelle (Gestodene and Levonorgestrel)
  Mithra, Belgium



• Gestoden Plus-Teva (Gestodene and Ethinylestradiol)
  Teva Pharma, Switzerland



• Gestoden/Ethinylestradiol 75/30 Berlipharm (Gestodene and Ethinylestradiol)
  Bayer, Denmark



• Gestoden/Ethinylestradiol 75/30 Schering (Gestodene and Ethinylestradiol)
  Bayer Schering Pharma, Denmark



• Gestodène/Ethinylestradiol Actavis (Gestodene and Ethinylestradiol)
  Actavis, France



• Gestodène/Ethinylestradiol Arrow (Gestodene and Ethinylestradiol)
  Arrow, France



• Gestodène/Ethinylestradiol Biogaran (Gestodene and Ethinylestradiol)
  Biogaran, France



• Gestodène/Ethinylestradiol EG (Gestodene and Ethinylestradiol)
  EG Labo, France



• Gestodène/Ethinylestradiol Ranbaxy (Gestodene and Ethinylestradiol)
  Ranbaxy, France



• Gestodène/Ethinylestradiol Ratiopharm (Gestodene and Ethinylestradiol)
  Ratiopharm, France



• Gestodène/Ethinylestradiol Sandoz (Gestodene and Ethinylestradiol)
  Sandoz, France



• Gestodène/Ethinylestradiol Teva (Gestodene and Ethinylestradiol)
  Teva Santé, France



• Gestodène/Ethinylestradiol Winthrop (Gestodene and Ethinylestradiol)
  Sanofi-Aventis, France



• Gestodène/Ethinylestradiol Zydus (Gestodene and Ethinylestradiol)
  Zydus, France



• Gestodette (Gestodene and Ethinylestradiol)
  Haupt, Bulgaria; LadeePharma, Slovakia



• Gestodiol (Gestodene and Ethinylestradiol)
  EG, Italy



• Gestofeme (Gestodene and Ethinylestradiol)
  Mithra, Belgium



• Gestonette (Gestodene and Ethinylestradiol)
  Sandoz, Denmark



• Ginera (Gestodene and Ethinylestradiol)
  Bayer, Turkey



• Ginoden (Gestodene and Ethinylestradiol)
  Bayer, Italy



• Gynera (Gestodene and Ethinylestradiol)
  Bayer, Switzerland; Bayer, Peru; Bayer, Taiwan; Bayer Schering Pharma, Vietnam; Schering, Bahrain; Schering, Oman; Schering, Portugal; Schering, Thailand



• Gynovin (Gestodene and Ethinylestradiol)
  Bayer, Austria; Bayer, Spain; Schering, Colombia; Schering, Dominican Republic



• Gyselle (Gestodene and Ethinylestradiol)
  Spirig Pharma, Switzerland



• Harmonet Gervasi (Gestodene and Ethinylestradiol)
  Gervasi, Spain



• Harmonet (Gestodene and Ethinylestradiol)
  Pfizer, Switzerland; Wyeth, Belgium; Wyeth, Colombia; Wyeth, Denmark; Wyeth, Estonia; Wyeth, Spain; Wyeth, France; Wyeth, Hungary; Wyeth, Italy; Wyeth, Lithuania; Wyeth, Latvia; Wyeth, Portugal; Wyeth, Slovenia; Wyeth, Slovakia; Wyeth, Venezuela



• Harmonette (Gestodene and Ethinylestradiol)
  Wyeth, Austria



• Hormofen (Gestodene and Ethinylestradiol)
  Gutis, Costa Rica



• Katya (Gestodene and Ethinylestradiol)
  Stragen, United Kingdom; Stragen, Slovakia



• Kipling (Gestodene and Ethinylestradiol)
  Effik, Italy



• Lindynette (Gestodene and Ethinylestradiol)
  Chemical Works, Slovenia; Farmagé, Peru; Gedeon Richter, Bulgaria; Gedeon Richter, Czech Republic; Gedeon Richter, Hungary; Gedeon Richter, Lithuania; Gedeon Richter, Latvia; Gedeon Richter, Vietnam; Pliva, Croatia (Hrvatska); Richter Gedeon RT, Slovakia; Sandoz, Denmark



• Logest (Gestodene and Ethinylestradiol)
  Bayer, Estonia; Bayer, Croatia (Hrvatska); Bayer, Lithuania; Bayer, Latvia; Bayer, Slovenia; Schering, Czech Republic; Schering, Slovakia



• Masbell (Gestodene and Ethinylestradiol)
  Chalver, Colombia



• Meliane (Gestodene and Ethinylestradiol)
  Bayer, Austria; Bayer, Belgium; Bayer, Spain; Bayer, Greece; Bayer Animal Health, Luxembourg; Berlis, Switzerland; Eurim, Austria; Schering, Colombia; Schering, Malta; Schering, Thailand



• Méliane (Gestodene and Ethinylestradiol)
  Bayer Santé, France



• Meliane (Gestodene and Gestodene)
  Bayer, Hungary



• Meloden (Gestodene and Ethinylestradiol)
  Bayer, Switzerland



• Melodene 15 (Gestodene and Ethinylestradiol)
  Bayer, Spain



• Melodene (Gestodene and Ethinylestradiol)
  Bayer Schering, South Africa



• Melodia (Gestodene and Ethinylestradiol)
  Bayer Schering, France



• Milligest (Gestodene and Ethinylestradiol)
  Gedeon Richter, Czech Republic; Gedeon Richter, Hungary; Sandoz, Denmark



• Milvane (Gestodene and Ethinylestradiol)
  Bayer, Switzerland; Bayer, Italy; Bayer Schering Pharma, Denmark



• Minero (Gestodene and Ethinylestradiol)
  Orifarm, Denmark



• Minesse (Gestodene and Ethinylestradiol)
  Pfizer, Switzerland; Wyeth, Austria; Wyeth, Czech Republic; Wyeth, Spain; Wyeth, France; Wyeth, Hungary; Wyeth, Italy; Wyeth, Malta; Wyeth, Oman; Wyeth, Portugal; Wyeth, Slovakia; Wyeth, Taiwan; Wyeth, Venezuela; Wyeth, South Africa



• Minigeste (Gestodene and Ethinylestradiol)
  Schering, Portugal



• Minulet (Gestodene and Ethinylestradiol)
  Pfizer, Switzerland; Wyeth, Austria; Wyeth, Australia; Wyeth, Belgium; Wyeth, Colombia; Wyeth, Costa Rica; Wyeth, Czech Republic; Wyeth, Germany; Wyeth, Denmark; Wyeth, Estonia; Wyeth, Spain; Wyeth, France; Wyeth, Guatemala; Wyeth, Honduras; Wyeth, Hungary; Wyeth, Italy; Wyeth, Lithuania; Wyeth, Latvia; Wyeth, Malta; Wyeth, Nicaragua; Wyeth, Netherlands; Wyeth, New Zealand; Wyeth, Oman; Wyeth, Panama; Wyeth, Portugal; Wyeth, Slovenia; Wyeth, El Salvador; Wyeth, Taiwan; Wyeth, Venezuela



• Minulette (Gestodene and Ethinylestradiol)
  Wyeth, South Africa



• Mirelle (Gestodene and Ethinylestradiol)
  Bayer, Austria; Bayer, Belgium; Bayer, Switzerland; Bayer, Estonia; Bayer, Lithuania; Bayer, Latvia; Bayer Animal Health, Luxembourg; Bayer Schering, South Africa; Schering, Czech Republic; Schering, Dominican Republic; Schering, Slovakia



• Modina (Gestodene and Ethinylestradiol)
  Orifarm, Denmark



• Moneva (Gestodene and Ethinylestradiol)
  Bayer Santé, France



• Myvlar (Gestodene and Ethinylestradiol)
  Berlis, Switzerland



• Perléane (Gestodene and Ethinylestradiol)
  Biogaran, France



• Phaeva (Gestodene and Ethinylestradiol)
  Bayer Santé, France



• Reginon (Gestodene and Ethinylestradiol)
  Koçak, Turkey



• Sunya (Gestodene and Ethinylestradiol)
  Stragen, United Kingdom; Stragen, Slovakia



• Sylgestrel (Gestodene andEthinylestradiol)
  Haupt, Bulgaria



• Sylvie (Gestodene and Ethinylestradiole)
  SymPhar, Poland



• Tri Minulet (Gestodene and Ethinylestradiol)
  Wyeth, Belgium



• Triadene (Gestodene and Ethinylestradiol)
  Bayer, United Kingdom



• Tri-Gynera (Gestodene and Ethinylestradiol)
  Schering, Portugal



• Trigynovin (Gestodene and Ethinylestradiol)
  Bayer, Spain



• Triminulet (Gestodene and Ethinylestradiol)
  Wyeth, Spain; Wyeth, Italy



• Tri-Minulet (Gestodene and Ethinylestradiol)
  Wyeth, Czech Republic; Wyeth, France; Wyeth, Portugal



• Triodeen (Gestodene and Ethinylestradiol)
  Bayer, Netherlands



• Triodena (Gestodene and Ethinylestradiol)
  Bayer, Austria; Bayer, Hungary



• Triodene (Gestodene and Ethinylestradiol)
  Bayer, Belgium; Bayer Animal Health, Luxembourg; Bayer Schering, South Africa



• Wave ratiopharm (Gestodene and Ethinylestradiol)
  Ratiopharm, Austria



• Yris (Gestodene and Ethinylestradiol)
  Kwizda, Austria

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IUPAC	International Union of Pure and Applied Chemistry
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.